In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||12 March 2008|
|PDF File Size:||16.34 Mb|
|ePub File Size:||7.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
Statistics presented where given by the authors. All these reasons can be grouped in three broad categories: Did you know that your browser is out of date? Views Read View averoes View history.
Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions. In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs. Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin?
The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. One may question each of these choices: This page was last modified on 3 Decemberat Eur Heart J ; Analyses are to time of first event.
Hospitalized apixabaj with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. Read your latest personalised notifications Sign in No account yet? Patients apixaan eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening. Assessment that INR could not or was unlikely to be measured at requested interval; 5.
The AVERROES Trial – Clinical Implications
There were 44 1. Based on averros indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.
The trial was terminated early given a treatment benefit with apixaban. Also, how does apixaban compare to aspirin rates of major bleeding? Sign in to My ESC. The New England Journal of Medicine.
Don’t miss out Read your latest personalised notifications Ok, got it. Apixaban is, at the time of writing, the best alternative to aspirin in patients deemed unsuitable for aveerroes K antagonists. Connolly SJ, et al. Yet, these proportions reflect the current underuse of VKAs in multiple registries.
Concurrent medications whose metabolism could be affected by VKAs; 9.
AVERROES – Wiki Journal Club
The primary outcome was stroke or systemic embolism. There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1. This proportion was similar for both academic and community hospitals. Presented as apixaban vs. Dabigatran versus warfarin in patients with atrial fibrillation. The median duration of follow-up was 1. Patients also needed to have at averroe one of the following risk factors for stroke: In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin.
Apixaban in Patients with Atrial Fibrillation. There were 51 primary outcome events in those randomised to apixaban 1.
With a mean follow-up of 1.